Cytomegalovirus immunoglobulin after thoracic transplantation: An overview

Transplantation

Volumn 100, Issue , 2016, Pages S1-S4

  Grossi, Paolo ^a   Mohacsi, Paul ^b   Szabolcs, Zoltán ^c   Potena, Luciano ^d  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN; VALGANCICLOVIR; CYTOMEGALOVIRUS-SPECIFIC HYPERIMMUNE GLOBULIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALLOGRAFT; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HOST RESISTANCE; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CONSENSUS DEVELOPMENT; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS; PASSIVE IMMUNIZATION; TREATMENT OUTCOME; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEART TRANSPLANTATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84959917854     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001094     Document Type: Review

References (55)

1. Roy S, Arav-Boger R. New cell-signaling pathways for controlling cytomegalovirus replication. Am J Transplant. 2014;14:1249-1258.
2. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002;10:332-339.
3. Kudchodkar SB, Yu Y, Maguire TG, et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol. 2004;79:11030-11039.
4. Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008;22:89-97.
5. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13:1203-1216.
6. Rodríguez-Serrano M, Sánchez-Lázaro I, Almenar-Bonet L, et al. Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation? Clin Transplant. 2014;28:88-95.
7. Andreassen AK, Andersson B, Gustafsson F, et al. SCHEDULE Investigators Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014;14:1828-1838.
8. Doesch AO, Repp J, Hofmann N, et al. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients. Drug Des Devel Ther. 2012;6:289-295.
9. Stern M, Hirsch H, Cusini A, et al. Members of Swiss Transplant Cohort Study Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98:1013-1018.
10. Johansson I, Mårtensson G, Nyström U, et al. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis. 2013;13:582.
11. Mitsani D, Nguyen MH, Kwak EJ, et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant. 2010;29:1014-1020.
12. Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidenceofcytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant. 2013;32:701-706.
13. Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150-162.
14. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761-769.
15. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ. Transplantation. 2013;96:333-360.
16. Koskinen PK, Kallio EA, Tikkanen JM, et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis. 1999;1:115-126.
17. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anticytomegalovirus approach for preventionof allograft vasculopathy inheart transplant recipients. J Heart Lung Transplant. 2009;28:461-467.
18. Petrakopoulou P, Kübrich M, Pehlivanli S, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation. 2004;110(11 Suppl 1):II207-II212.
19. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis. 2001;3(Suppl 2):44-48.
20. Koskinen PK, Nieminen MS, Krogerus LA, et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant. 1993;12:724-729.
21. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant. 2011;11:2190-2196.
22. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391-1396.
23. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146:1419-1425.
24. Johansson I, Mårtensson G, Andersson R. Cytomegalovirus and longterm outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis. 2010;42:129-136.
25. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis. 2008;46:831-839.
26. Waldman WJ, Knight DA, Adams PW, et al. Invitro induction of endothelial HLA class II antigen expression by CMV-activated CD4+ T cells. Transplantation. 1993;56:1504-1512.
27. Tikkanen JM, Krebs R, Bruggeman C, et al. Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allograft. Transplantation. 2004;77:655-658.
28. Danziger-Isakov LA, Worley S, Michaels MG, et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation. 2009;87:1541-1548.
29. Costa C, Curtoni A, Sidoti F, et al. Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients. Arch Virol. 2013;158:1461-1465.
30. Schlischewsky E, Fuehner T, Warnecke G, et al. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis. 2013;15:60-69.
31. Snydman DR, Limaye AP, Potena L, et al. Update and review: state-of-the art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43(Suppl 3):S1-S17.
32. Laske A, Gallino A, Mohacsi P, et al. Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation. Transplant Proc. 1991;23(1 Pt 2):1170-1173.
33. Snydman DR, Kistler KD, Ulsh P, et al. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant patients. Transplantation. 2010;90:1432-1438.
34. Snydman DR, Kistler KD, Ulsh P, et al. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clin Transplant. 2011;25:E455-E462.
35. Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus management practices in lung. Transplantation. 2010;90:672-676.
36. Le Page AK, Jager MM, Kotton CN, et al. International survey ofcytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95:1455-1456.
37. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACTstudy. Transplantation. 2010;90:1427-1431.
38. Gupta S, Mitchell JD, Markham DW, et al. High incidence of cytomegalovirus disease in D+/R-heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis. J Heart Lung Transplant. 2008;27:536-539.
39. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635-1642.
40. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3-vs 12-month valganciclovir therapy. J Heart Lung Transplant. 2009;28:670-675.
41. Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30:990-996.
42. Vrtovec B, Thomas CD, Radovancevic R, et al. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin preemptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant. 2004;23:461-465.
43. Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012;12:2457-2464.
44. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant. 2007;26:1019-1024.
45. Schoeppler KE, Lyu DM, Grazia TJ, et al. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant. 2013;13:376-382.
46. Zürcher S, Mooser C, Lüthi AU, et al. Sensitive and rapid detection of ganciclovir resistance by PCR based MALDI-TOF analysis. J Clin Virol. 2012;54:359-363.
47. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153-1183.
48. Asberg A, Humar A, Jardine AG, et al. VICTOR Study Group Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9:1205-1213.
49. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant. 2003;22:250-257.
50. Aguado JM, Gomez-Sanchez MA, Lumbreras C, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother. 1995;39:1643-1645.
51. Data on file, Biotest® AG, Dreieich, Germany.
52. Freeman R, Gould FK, McMaster A. Management of cytomegalovirus antibody negative patients undergoing heart transplantation. J Clin Pathol. 1990;43:373-376.
53. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12-28.
54. Humar A, Syndman D, ST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78-86.
55. Razonable RR, Humar A. Cytomegalovirus. Chapter 14. The AST Handbook of Transplant Infections. 2011 (1st ed). Blackwell Publishing Ltd. Ed. Kumar D, Humar A.